Ipsos Healthcare Debuts Pan-Cancer Testing Monitor

Ipsos Healthcare has launched a new syndicated study called the 'Pan-Cancer Testing Monitor', which measures and tracks the usage of pan-cancer tests designed to assess a wide range of cancer types. The study currently covers the US but will be rolled out in other markets at a later stage.

As part of the firm's Oncology Molecular Diagnostics portfolio, the new study gathers perceptions from medical oncologists and pathologists on topics such as awareness and current utilisation of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, the monitor incorporates de-identified patient record forms for patients recently given a pan-cancer test. These forms detail information such as brand used, reason for testing, reasons for brand choice, treatment impact, test outcome, and satisfaction with test.

Pieter De Richter, Head of the division's Molecular Diagnostics Portfolio, comments: 'As this study has been designed to focus specifically on this subset of patients, it allows us to get an accurate and robust read on the use of these test panels. Brand share tracking is but one aspect of this study, however - it also provides detailed insights into the drivers for and barriers to usage of these panels, the decision-making processes that influence uptake and, importantly, the impact of using pan-cancer testing panels on treatment choice'.

The initial wave of the new monitor covers solid tumours, and Ipsos is planning to launch a similar study for pan-cancer tests in haematological malignancies.

Web site: www.ipsos.com .